Investing.com -- Sarepta Therapeutics Inc (NASDAQ: SRPT) stock tumbled 10% following the announcement that the U.S. Food and Drug Administration has placed a clinical hold on the company’s ...

Sarepta stock has tanked. Most investors don’t see the drugmaker’s executive management as credible following the failure to disclose a patient death, a BMO survey suggests.

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Evotec shares dipped 11.3% to $3.78 in the pre-market trading session. Here are some other stocks moving lower in pre-market trading.